For research use only. Not for therapeutic Use.
Almitrine Dimesylate (marketed as Duxil by Servier) is a diphenylmethylpiperazine derivative classified as a respiratory stimulant by the ATC. It enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep.
| Catalog Number | I002228 |
| CAS Number | 29608-49-9 |
| Synonyms | Vectarion; Almitrin; Almitrina; Almitrinum; Almitrine.;6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-N,N/’-diprop-2-enyl-1,3,5-triazine-2,4-diamine |
| Molecular Formula | C28H37F2N7O6S2 |
| Purity | ≥95% |
| Target | Potassium Channel |
| Solubility | Soluble in DMSO, not in water |
| Storage | Store at 0-8 °C |
| IUPAC Name | 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-N,4-N-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine;methanesulfonic acid |
| InChI | InChI=1S/C26H29F2N7.2CH4O3S/c1-3-13-29-24-31-25(30-14-4-2)33-26(32-24)35-17-15-34(16-18-35)23(19-5-9-21(27)10-6-19)20-7-11-22(28)12-8-20;2*1-5(2,3)4/h3-12,23H,1-2,13-18H2,(H2,29,30,31,32,33);2*1H3,(H,2,3,4) |
| InChIKey | MRDBGMJEPGXQHJ-UHFFFAOYSA-N |
| SMILES | CS(=O)(=O)O.CS(=O)(=O)O.C=CCNC1=NC(=NC(=N1)N2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)NCC=C |
| Reference | </br>1: Bouhemad B, Barbry T, Soummer A, Lu Q, Rouby JJ. Doppler study of the effects of inhaled nitric oxide and intravenous almitrine on regional pulmonary blood flows in patients with acute lung injury. Minerva Anestesiol. 2014 May;80(5):517-25. Epub 2013 Dec 4. PubMed PMID: 24299918.</br>2: Bermejo S, Gallart L, Silva-Costa-Gomes T, Vallès J, Aguiló R, Puig MM. Almitrine fails to improve oxygenation during one-lung ventilation with sevoflurane anesthesia. J Cardiothorac Vasc Anesth. 2014 Aug;28(4):919-24. doi: 10.1053/j.jvca.2013.03.019. Epub 2013 Sep 7. PubMed PMID: 24016684.</br>3: Yang W, Liu M, Teng J, Hao Z, Wu B, Wu T, Liu GJ. Almitrine-Raubasine combination for dementia. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD008068. doi: 10.1002/14651858.CD008068.pub2. Review. PubMed PMID: 21412915.</br>4: El-Sayed MA. Stability-indicating methods for the determination of a mixture of almitrine and raubasine by derivative spectrophotometry. Drug Test Anal. 2009 Jun;1(6):279-85. doi: 10.1002/dta.48. PubMed PMID: 20355207.</br>5: Titova ON, Ignat/’ev VA, Didur MD, Kameneva MIu, Sukhovskaia OA. [Combination of thiotropium bromide with almitrine and pulmonary rehabilitation in the treatment of patients with chronic obstructive pulmonary disease]. Ter Arkh. 2008;80(3):28-33. Russian. PubMed PMID: 18441680.</br>6: Payen DM, Muret J. Nitric oxide and almitrine: the definitive answer for hypoxemia. Curr Opin Anaesthesiol. 1999 Feb;12(1):37-42. PubMed PMID: 17013295.</br>7: Silva-Costa-Gomes T, Gallart L, Vallès J, Trillo L, Minguella J, Puig MM. Low- vs high-dose almitrine combined with nitric oxide to prevent hypoxia during open-chest one-lung ventilation. Br J Anaesth. 2005 Sep;95(3):410-6. Epub 2005 Jul 15. PubMed PMID: 16024585.</br>8: Li S, Long J, Ma Z, Xu Z, Li J, Zhang Z. Assessment of the therapeutic activity of a combination of almitrine and raubasine on functional rehabilitation following ischaemic stroke. Curr Med Res Opin. 2004 Mar;20(3):409-15. PubMed PMID: 15025850.</br>9: Dalibon N, Moutafis M, Liu N, Law-Koune JD, Monsel S, Fischler M. Treatment of hypoxemia during one-lung ventilation using intravenous almitrine. Anesth Analg. 2004 Mar;98(3):590-4, table of contents. PubMed PMID: 14980903.</br>10: Górecka D, Sliwiński P, Pałasiewicz G, Pachocki R, Zieliński J; Almitrine Study Group. Effects of almitrine bismesylate on arterial blood gases in patients with chronic obstructive pulmonary disease and moderate hypoxaemia: a multicentre, randomised, double-blind, placebo-controlled study. Respiration. 2003 May-Jun;70(3):275-83. PubMed PMID: 12915747. </br> </br> |
